NCT02679560 is a Phase 2 clinical trial of Liposomal Bupivacaine in Femoral Fractures, sponsored by Ian Elliott Brown.

Who is sponsoring NCT02679560?

NCT02679560 is sponsored by Ian Elliott Brown.

What drugs are being tested in NCT02679560?

Interventions in NCT02679560: Liposomal Bupivacaine, Ropivacaine HCL.

What condition does NCT02679560 study?

NCT02679560 studies Femoral Fractures.

Is NCT02679560 still recruiting?

NCT02679560 is currently terminated. Last updated 21 February 2021.

Are results published for NCT02679560?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-02-21 · How we verify

NCT02679560

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Liposomal Bupivacaine for Acute Pain in Hip and Femur Fractures

Terminated Phase 2 Results posted Last updated 21 February 2021

What this trial tests

Phase 2 trial testing Liposomal Bupivacaine in Femoral Fractures in 3 participants. Terminated before completion.

Timeline

1 October 2017

Primary endpoint
1 November 2019

1 November 2019

Quick facts

Lead sponsor	Ian Elliott Brown
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	3
Start date	1 October 2017
Primary completion	1 November 2019
Estimated completion	1 November 2019
Sites	1 location across United States

Drugs / interventions tested

Liposomal Bupivacaine — full drug profile →
Ropivacaine HCL

Conditions studied

Femoral Fractures — all drugs for Femoral Fractures →

Sponsor

Ian Elliott Brown

Who can join

Adults 18 to 70, any sex, with Femoral Fractures. Patients with the condition only — healthy volunteers not accepted.

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse event data were collected for the duration of the participant's hospital stay up to 96 hours.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Liposomal Bupivacaine

Serious: 0/1 (0%)

Deaths: 0/1

Ropivacaine HCL

Serious: 0/2 (0%)

Deaths: 0/2

Other adverse events (14 terms — click to expand)

Reaction	System	Liposomal Bupivacaine	Ropivacaine HCL
Mild edema	Blood and lymphatic system disorders	—	—
mild muscle spasms	Musculoskeletal and connective tissue disorders	—	—
hallucination	Psychiatric disorders	—	—
pruritus	Skin and subcutaneous tissue disorders	—	—
diaphoresis	Nervous system disorders	—	—
urinary retention	Renal and urinary disorders	—	—
fever	Immune system disorders	—	—
elevated systolic blood pressure	Blood and lymphatic system disorders	—	—
tachypnea	Respiratory, thoracic and mediastinal disorders	—	—
tachycardia	Cardiac disorders	—	—
nausea	Gastrointestinal disorders	—	—
constipation	Gastrointestinal disorders	—	—
moderate orthostatic hypotension	Nervous system disorders	—	—
anemia	Blood and lymphatic system disorders	—	—

Data from ClinicalTrials.gov NCT02679560 adverse events section.

Sponsor's own description

This is an investigator-initiated, single-center, randomized, patient blinded, controlled trial. The purpose of this study is to compare the effect of a fascia iliaca compartment block (FICB) using 0.2% ropivacaine vs. liposomal bupivacaine in patients with femur and/or hip fractures admitted to the University of California Davis Medical Center (UCDMC). The primary endpoint will be the total opioid requirements during the 96 hour randomization period with secondary endpoints including total daily opioid requirements for days 1-4, duration of effect and objective pain scores using the numeric rating scale (NRS) during their hospital stay.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Liposomal Bupivacaine

Trials testing the same drug.

NCT06284434 — Liposomal Bupivacaine Use in Alveolar Bone Graft Patients · Phase 3 · recruiting
NCT05891613 — A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction · Phase 4 · completed
NCT06411795 — Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatodu · Phase 2 · recruiting
NCT05177991 — Post-operative Pain Control-TAP Block Using Exparel vs. Marcaine for Hernia Repairs · EARLY_PHASE1 · active not recruiting
NCT05044468 — EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Ca · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02679560 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ian Elliott Brown
Last refreshed: 21 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02679560.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing